The greatest achievement in the treatment of obesity and diabetes would be the development of bariatric/metabolic surgery. At the beginning, bariatric surgeries were developed to simply reduce body weight in morbidly obese subjects. Before long, it was discovered that diabetes and other metabolic complications of obesity could be placed in remission. The remission rate of diabetes after bariatric surgery is strikingly high and, in the case of Roux-en-Y gastric bypass surgery, diabetes remission commonly occurs immediately after the surgery, when significant weight loss does not take place. Therefore, the concept of bariatric surgery has evolved into metabolic surgery. Physiologic changes in gastrointestinal endocrine system following the anatomical changes made by bariatric/metabolic surgery are regarded as the major mechanisms of weight loss and diabetes remission. In this regard, the foregut and hindgut hypotheses were suggested as the mechanisms associated with diabetes remission. With the advent of sleeve gastrectomy, which does not bypass the foregut (duodenum and proximal jejunum) but increases the secretion of glucagon-like peptide-1, the foregut hypothesis is currently under attack. However, a single mechanism is not enough to explain the metabolic effect of bariatric/metabolic surgery. Further studies are warranted to elucidate the mechanisms of metabolic improvements after bariatric/metabolic surgery. ( 
. Physiologic mechanismof the development and remission of type 2 diabetes. The horizontal axis represents insulin sensitivity and the vertical axis represents pancreatic beta cell function, or insulin secretory capacity. The dotted line represents the relationship between insulin sensitivity and insulin secretory capacity in subjects with normal glucosetolerance. (A) In subjects with normal glucose tolerance, as insulin sensitivity decreases, insulin secretion increases in a compensatory manner (white circles). To the contrary, in subjects who would developtype 2 diabetes, the compensatory insulin secretion in response to the decreasing insulin sensitivity is generally absent, which results in impaired glucose tolerance (black square, I) or overt diabetes (black square, D). (B) Physiologic changes in glucose homeostasis after Roux-en-Y gastric bypass surgery in subjects with morbid obesity. This graph is drawn based on the previously published data [69] . In subjects with normal glucose tolerance, insulin sensitivity dramatically improves with time(white circles). Notably, the improvement in insulin sensitivity is remarkable during the first postoperative week, when there is no significantweight loss takes place. Thereafter, further improvementsin insulin sensitivity could be largely explained by progressive weight loss up to 1 year after the surgery. In subjects with type 2 diabetes, both beta cell function and insulin sensitivity show significant improvement after Roux-en-Y gastric bypass (black squares). The improvements in insulin sensitivity is also prominent during the first postoperative week. 
